99 related articles for article (PubMed ID: 2214148)
1. [Diagnosis: tumor marker].
Inaba N; Takamizawa Y; Ota J; Fukazawa K
Gan No Rinsho; 1990 Aug; 36(10):1123-7. PubMed ID: 2214148
[TBL] [Abstract][Full Text] [Related]
2. Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Schauenstein E; Lahousen M; Weblacher M; Steinschifter W; Estelberger W; Schauenstein K
Cancer; 1996 Aug; 78(3):511-6. PubMed ID: 8697398
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic significance of tumor markers for gynecologic malignancies].
Aoki D; Hirasawa A; Susumu N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
[TBL] [Abstract][Full Text] [Related]
4. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
5. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
Kimura E; Kobayashi S; Terashima Y
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
[TBL] [Abstract][Full Text] [Related]
6. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
7. [Gynecologic malignancies].
Kato H
Nihon Rinsho; 1996 Jun; 54(6):1637-41. PubMed ID: 8691622
[TBL] [Abstract][Full Text] [Related]
8. [Development and clinical research of computer aided multivariate pattern analysis system (CAMPAS) OV-1 for diagnosis of ovarian carcinoma].
Kobayashi S; Murae M; Kimura E
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):241-8. PubMed ID: 8492011
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers for the diagnosis, prognosis, treatment and follow-up of gynaecological tumors.
Ulsperger E; Karrer K
Bull Soc Sci Med Grand Duche Luxemb; 1989; 126(1):33-43. PubMed ID: 2545372
[TBL] [Abstract][Full Text] [Related]
10. [Tumor markers in uterine cancers].
Fukasawa I; Kousaka N; Kun Z; Inaba N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
[TBL] [Abstract][Full Text] [Related]
11. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
13. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in gynecological and breast cancer].
Jobo T; Sato R; Kuramoto H
Rinsho Byori; 2003 Dec; 51(12):1188-94. PubMed ID: 14743742
[TBL] [Abstract][Full Text] [Related]
15. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of different serum tumor markers in gynecological malignancies.
Paulick R; Caffier H; Horner G; Lang K; Filbry E
Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031
[TBL] [Abstract][Full Text] [Related]
17. [Importance of CA-50 detection in malignant gynecologic tumors].
Indraccolo SR; Greco A; Cartechini MG; Compagnucci P
Minerva Ginecol; 1990 Dec; 42(12):507-9. PubMed ID: 2089292
[TBL] [Abstract][Full Text] [Related]
18. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
19. [CEA monitoring of gynecologic tumor patients using a simplified CEA-radioimmunoassay].
Hörst M; Wiest W
Fortschr Med; 1982 Mar; 100(11):482-3. PubMed ID: 7076078
[No Abstract] [Full Text] [Related]
20. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
